Akers Biosciences Share Discussion Threads

[rivaldo] 02/4/2015 14:10

Up in the USA to $4.86 on the open, or around 325p.

[norbus] 02/4/2015 09:43

mcm

This route to market may prove better than some;

[mcmather] 02/4/2015 09:13

It's of interest given the continual mantra of our products save time AND money; costs perhaps slightly more applicable to the public sector than the private sector?

However, this is nothing new per se re 15 Dec 2009:

"Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid
diagnostic screening and testing products, has obtained a United States
Government Service Administration (GSA) Schedule contract. The
Contract, number GS-07F-0140W, applies to a variety of the Company's single-use
assays including the PIFA Heparin/PF4 Rapid Assay, BreathScan breath alcohol
detectors and the custom BreathScan keychain unit which is currently in use by
the US Military as part of their Personally Owned Vehicle (POV) Safety Program."

[someuwin] 02/4/2015 08:12

This must be too cheap now - surely?

[rivaldo] 02/4/2015 07:07

This sounds like terrific news today - if AKR can sell into the US Government then other customers and markets will fall like dominoes:



ADS Inc is "the world’s premier equipment, procurement, and support solutions specialist to the military, law enforcement, first responders, and the defense industry".....

[mcmather] 25/3/2015 23:13

Transcript for the earnings call; you may need to register (free and you can always then immediately unsubscribe) to read it all:

[mcmather] 25/3/2015 00:02

Rivlado, the stuff about heparin sales increase appears to be the usual smoke and mirrors from Dr Mitty.

Historically, sales of the device have been around the $1-$1.2m mark.

The results for 2008 - device sales of $1.037m.

The results for 2009 alluded to sales of the device outside of the US.

The results for 2010 alluded to a 37% increase in PIFA Heparin/PF4 Rapid Assay sales over 2009; this represents a strong acceleration in H2 2010. Of course, see above.

The results for 2011 alluding to Revenue for the Company's flagship PIFA Heparin/PF4 Rapid Assay: $1.1 million (2010: $940k). Again see above.

2012 - Sales of the Heparin/PF4 Rapid Assays slightly increased in 2012. However, the growth in sales only picked up in the fourth quarter as the Company began to benefit from the strategy of its dedicated technical sales account executives moving away from a direct selling model to one that works in tandem with over 300 sales representatives of ABI's US distribution partners, Cardinal Health and Fisher HealthCare. The good news is that this growth has continued into the current fiscal year.

2013 - This reorganization and the need to build relationships with distributor representatives hampered 2013 domestic sales growth but set the stage for an enhanced selling effort in 2014.

The tie up with Novotek Therapeutics has been known about / revenue pencilled in since 26 Nov 2012; ie the $1m shipping order here is not 'new' per se.

Take that away and the figures for total device sales are once again around the historic figure of $1m-$1.2m despite all the new fangled sales people and strategies that is continually blurted about.

The prospect of the deal with Novotek is at least something. However, if in the 6 years between that figure of $1.037m and the figures for 2014, sales of the device have only increased (inflation??) by $100k or so, is this cause for optimism or is this another attempt to juggle and bewilder by the king clown?

[rivaldo] 24/3/2015 13:57

Presentation dated 18th March is here:



Standouts for me are:

- five products launched and commercialized, pipeline will result in eleven products in market by end of 2016
- Heparin test has potential to save a typical U.S. hospital well over $1m annually

The results conference call is here, will try to listen soon:

[rivaldo] 24/3/2015 11:02

From Finncap this morning re the results - they also note the $9.7m of net cash:

"Akers Biosciences*: Prelims (CORP)

Revenues and EBITDA were in line with our estimates at US$4.4m (24% YoY growth) and US$-2.1m, respectively. Sales of the rapid test to detect a potentially fatal allergy to the blood thinner Heparin (PIFA Heparin/PF4) increased by 110% to $2.2m. With the global roll-out of PIFA Heparin/PF4 in China and Europe continuing, we anticipate further growth in 2015. We reiterate our 310p target price and make no changes to our forecasts."

[algernon2] 23/3/2015 15:45

I see Clean Air Power (as Tipped here by Norbus a short while ago as an alternative investment to Akers)has gone down almost 35% today.
Lets hope he was just as wrong about Akers.

[mcmather] 23/3/2015 10:54

The Company’s total revenue for the year ended December 31, 2014 was $4,427,174.

[sharesoc] 21/3/2015 12:35

AKERS BIOSCIENCES are presenting at our next growth company seminar on April 21st, investors and potential shareholders may be interested in attending. More details and registration at...

[rivaldo] 19/3/2015 08:29

Cheers mcmather - and here's the RNS confirming results on Monday:



I note that shareholders can ask questions via a conference call the same day - mcmather, Norbus, here's your ideal opportunity :o))

[werewolfie] 19/3/2015 06:42

I'm not complaining about the rise - i just wish it was based on something more positive such as improved sales or profit

[mcmather] 18/3/2015 22:26

Agree Norbus re 2807. Just a shame the game appears less about creating something other than one's own feathery nest; that might create some genuine interest and volume to have a bit of proper fun.

[mcmather] 18/3/2015 22:19

Rivaldo, the results - on nasdaq they need to be released within 3 months of the closing period - are to be announced on Monday:

[mcmather] 18/3/2015 22:17

WW, it is as rivaldo has said; Akers is dual listed. The price on Nasdaq is around $4.50. The equivalent in GBP is around £3.06.

Technicals might be behind the rise on Nasdaq; see the channel that has formed from around mid-November 2014 to where it is today.

The likes of barchart is all "BUY";

There is also the possibility of 20 day moving average breaking through the 50 day moving average;

Re moving averages, etc;

The likes of British Bulls (UK / AIM) also suggested 'long' yesterday but their 'indicators' can and often change from day to day:

[werewolfie] 18/3/2015 17:42

Good close today - however - other than someone listening to the doctors hot air, I cant think of a substantial reason for the increase

[rivaldo] 18/3/2015 08:45

Excellent close in the USA last night, up 14% to $4.51, or the equivalent of 300p here.

Most importantly, it was on decent volumes too with 82k shares traded.

Hopefully the precursor to some news (unlikely to be the prelims for another week or two I'd have thought).

[norbus] 17/3/2015 16:59

mcm
Akers looks to me a weirdo; watch him talk on a video. he lives both physically and mentally in a white coat; If you are not down, take your money, or most of it and run. AKR will not turn into Google or Apple

[mcmather] 16/3/2015 23:42

Rivaldo, all shareholders would welcome recurring revenue streams, new contracts, etc. Since 2007 the 'stellar' performer for Akers has been the PIFA PF4 / Heparin device. Whilst revenue has been 'recurring' this has stagnated around the $0.8m-$1.2m mark despite numerous new fangled sales strategies and individuals; eg Edwin C Hendrick.

Time will no doubt reveal what will come of the PIFA sales in China but simply based on the past 13 years the company has been trading on AIM, sadly, extreme caution dictates in my opinion.

In the middle of 2014 we commented upon here as to how any company could sell themselves to new investors at $5.50 (Nasdaq IPO) and then, very shortly after the listing, award warrants at just under $4 to 'key personnel'. What precisely had those staff members achieved between the IPO and the award of those warrants? The results to be released shortly will presumably highlight the basis for such an award??

The company may try to explain such away but the harsh reality is that any investor who participated in the Nasdaq IPO was then royally shafted (by those warrants) by the very same people they were hoping would fulfil what was said in the build up to the listing and what has continually been said by the likes of Dr Raymond Akers jnr and Dave Gentry since the IPO; big year / a $100m company / Knock it out of the park / etc.

The share price has not really exceeded that $4 mark since. If the warrants are not pure and simple greed, for the reason alluded to above, they make no sense from the perspective of the company which is, of course, owned by the shareholders including all those who participated in the Nasdaq IPO.....